DJIA 17,416.85 225.48 1.31%
NASDAQ 4,683.41 45.41 0.98%
S&P 500 2,021.25 19.09 0.95%
market minute promo


company name or ticker

UPDATE: Stifel Upgrades Clovis Oncology On Favorable Risk/Reward

Will This Analyst Upgrade Help Clovis Oncology (CLVS) Stock Today? (Update)

Sector Update: Technology Shares Flat Pre-Market; Clovis Oncology Upgraded to Buy at Stifel Nicolaus

Sector Update: Healthcare Healthcare

ASCO: Cancer Drug Showdown

Ariad, Pharmacyclics, and Johnson & Johnson present impressive data. Clovis battles with AstraZeneca.

The 3 Biggest Biotech Crashes in May

Here's what you need to know about tumbling shares in Insys, Clovis, and Aegerion.

Citi Downgrades Clovis, Rates It As High Risk

Why Clovis Oncology (CLVS) Stock Hit a One-Year Low Today

Why Clovis Oncology Inc. Shares Were Clobbered Again

Clovis shares take a beating following ASCO data and analyst commentary. Find out what investors' best course of action is going forward.

Stocks Hitting 52-Week Lows

See More Articles...